Al Tameemi, W. (2021). New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy. , 21(2), 131-133. doi: 10.52573/ipmj.2021.174604
Waseem F. Al Tameemi. "New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy". , 21, 2, 2021, 131-133. doi: 10.52573/ipmj.2021.174604
Al Tameemi, W. (2021). 'New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy', , 21(2), pp. 131-133. doi: 10.52573/ipmj.2021.174604
Al Tameemi, W. New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy. , 2021; 21(2): 131-133. doi: 10.52573/ipmj.2021.174604

New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy

Iraqi Postgraduate Medical Journal
Editorial, Volume 21, Issue 2, 2022, Pages 131-133    PDF (136.44 K)
DOI: 10.52573/ipmj.2021.174604
Author
Waseem F. Al Tameemi
Department of Hematology, College of Medicine, Al-Nahrain University, Baghdad, Iraq. Iraqi cultural attaché-Amman, Department of Scholarships and Cultural Relations, Ministry of Higher Education and Scientific Research. Iraq
Abstract
  Diffuse large B cell Non Hodgkin lymphoma (DLBCL) is the most frequent subtype, accounts for 30%–40% of cases. The disease is usually aggressive but there is high chance of cure with appropriate treatment lines.
References
  1. The Non-Hodgkin’s Lymphoma Classification Project NHLCP .A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood. 1997; 89:3909-3918. https://doi.org/10.1182/blood.V89.11.3909
  2. Ott. German. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. British Journal of Haematology, 2017, 178, 871–87. doi: 10.1111/bjh.14744.
  3. Philip Th, Guglielmi C, Hagenbeek A, Somers R, Der Lelie HV, Bron D, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. N Engl J Med 1995; 333:1540-1545. doi: 10.1056/NEJM199512073332305
  4. Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, et al. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology 2010 28:27, 4184-4190. DOI: 10.1200/JCO.2010.28.1618
  5. Adaniya  SS and Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current dataand potential applications on risk stratification and management. Am J Hematol. 2021 :1;96:617–29.
  6.  Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology 2012 30:28, 3452-3459. DOI: 10.1200/JCO.2011.41.0985
  7. Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH,et al. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.Journal of Clinical Oncology 2019 37:35, 3359-3368. DOI: 10.1200/JCO.19.00743.
  8. Tilly H, Morschhauser F , Bartlett NL, Mehta A , Salles G , Haioun C et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019;20:998.DOI:https://doi.org/10.1016/S1470-2045(19)30091-9
  9. Neelapu SS, Locke FL, Bartlett NL, Lekakis L J, Miklos DB, Jacobson CA, Braunschweig I, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017;377:2531-44. DOI: 10.1056/NEJMoa1707447
10. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380:45-56. DOI: 10.1056/NEJMoa1804980

11. Salles G, Duell  J, Barca EG , Tournilhac O, W, Liberati AM, et al.Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978. https://doi.org/10.1016/S1470-2045(20)30225-4

12. Maerevoet M, Zijlstra JM, Follows G, et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. J Hematol Oncol. 2021;14(1):111. Published 2021 Jul 16. doi:10.1186/s13045-021-01122-1

13. Hutchings M, Offner FC, Bosch F, Gritti G, Carlo-Stella C, Walter H, et al. Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. Blood2020 ; 136, Supplement 1,16-17. https://doi.org/10.1182/blood-2020-136571.

Statistics
Article View: 268
PDF Download: 99


Journal Management System. Powered by iJournalPro.com